title: Clinical characteristics of peripheral exudative hemorrhagic chorioretinopathy and its response to bevacizumab therapy.
authors.forename: E Y
authors.initials: EY
authors.lastname: Pinarci
authors.forename: I
authors.initials: I
authors.lastname: Kilic
authors.forename: S A
authors.initials: SA
authors.lastname: Bayar
authors.forename: S
authors.initials: S
authors.lastname: Sizmaz
authors.forename: I
authors.initials: I
authors.lastname: Akkoyun
authors.forename: G
authors.initials: G
authors.lastname: Yilmaz
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D056833:Central Serous Chorioretinopathy / Q000150:complications / Q000188:drug therapy*; D005122:Exudates and Transudates; D005260:Female; D006801:Humans; D008297:Male; D012166:Retinal Hemorrhage / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab